Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up

被引:82
作者
Pietrangeli, Alberto
Leandri, Massimo
Terzoli, Edmondo
Jandolo, Bruno
Garufi, Carlo
机构
[1] Ist Regina Elena, Dept Neurol, IT-00144 Rome, Italy
[2] Ist Regina Elena, Dept Med Oncol, IT-00144 Rome, Italy
[3] Univ Genoa, Interuniv Ctr Pain Neurophysiol, I-16126 Genoa, Italy
[4] Natl Inst Canc Res, Genoa, Italy
关键词
oxaliplatin; colorectal cancer; neurotoxicity; neuropathy; quality of life;
D O I
10.1159/000094376
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxaliplatin (L-OHP) has become a standard treatmentfor advanced colorectal cancer and a valid option for patients in the adjuvant setting. Compared with cisplatin, L-OHP has no renal toxicity, only mild hematological and gastrointestinal toxicity, while neurotoxicity is the limiting toxicity. This side effect has been described as a transient distal clysesthesia, enhanced by exposure to cold, and as a dose-related cumulative mild sensitive neuropathy. We studied two groups of patients (18 and 13) with advanced colorectal cancer, treated with median cumulative doses of L-OHP 862 mg/m(2) and 1,033.5 mg/m(2). All the patients had been evaluated previously, during treatment, after discontinuation and after a long follow-up of 5 years to verify the incidence and the characteristics of the neuropathy induced by this antineoplastic agent. The clinical and neurophysiological examinations showed an acute and transient neurotoxicity and a cumulative dose-related sensory neuropathy in nearly all the patients. The reversibility of these effects was studied. Five patients continue to manifest symptoms and signs of neurotoxicity after a long follow-up, indicating persistence of this peculiar type of neuropathy. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:13 / 16
页数:4
相关论文
共 19 条
  • [1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [2] Oxaliplatin (L-OHP): a new reality in colorectal cancer
    Bleiberg, H
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (Suppl 4) : 1 - 3
  • [3] Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial
    Cascinu, S
    Catalano, V
    Cordella, L
    Labianca, R
    Giordani, P
    Baldelli, AM
    Beretta, GD
    Ubiali, E
    Catalano, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3478 - 3483
  • [4] CAVALETTI G, 1992, CANCER-AM CANCER SOC, V69, P203, DOI 10.1002/1097-0142(19920101)69:1<203::AID-CNCR2820690133>3.0.CO
  • [5] 2-1
  • [6] Oxaliplatin-associated neuropathy: A review
    Cersosimo, RJ
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) : 128 - 135
  • [7] Extra JM, 1998, SEMIN ONCOL, V25, P13
  • [8] GARUFI C, 1999, P ASCO 35 ANN M LOS, V244, P938
  • [9] GIACCHETTI S, 2004, P ASCO 40 ANN M NEW
  • [10] Grothey Axel, 2005, Clin Colorectal Cancer, V5 Suppl 1, pS38, DOI 10.3816/CCC.2005.s.006